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Poster Session-I 89HCoV infection developed LRI. BAL was performed in 38 (18%)
patients, 6 of whom had HRhV detection in upper respiratory sam-
ples. Two of these BALs tested positive for HRhV.
Conclusion:This prospective study is the first to describe the nat-
ural history of HCoV and HRhV infections during the first 100 days
after HCT. HRhV and HCoV infections were common and pro-
longed shedding may occur. While HRhV frequently caused symp-
tomatic URI and occasionally LRI, there was no apparent
association with either URI or LRI in patients infected with
HCoV in this study group. However, this study does not exclude
the possibility that HCoV is a rare cause of lower tract disease. Stud-
ies are on-going to further investigate this.244
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Based on encouraging phase II data, we prospectively tested the
combination of tacrolimus and sirolimus (tacro/siro) as GVHD pro-
phylaxis in patients undergoing HLA-matched sibling donor HCT.
Eighty-five patients were stratified according to conditioning regi-
men as follows: fludarabine-melphalan (FluMel: n 5 46); FTBI-
VP16 (TBI: n 5 28), and busulfan-cyclophosphamide (BuCy: n 5
11).Themedian agewas 47 years (range: 10–67).The patient diagno-
ses were AML (33), ALL (18), NHL/HD (11/3), MDS (6), CML (5),
myeloma (3), MPD (3), and CLL (1). A majority of patients received
a PBSC graft except for five who received a BM graft with the overall
median CD341 cell dose of 5.1  106/kg (range: 1.7–10.5). All pa-
tients engrafted (median neutrophil engraftment: 15 days). Fifty
five of 85 patients are alive after a median follow up of 26 months
(range: 14–37). Twenty-two patients died of relapse while eight
were due to non-relapse causes including acute/chronic GVHD (3),
multi-organ failure (1), mucormycosis (1), leukoencephalopathy (1),
and respiratory failure (1). The probabilities of overall survival
(OS), disease-free survival (DFS), and relapse at 2 years were 66%
(CI: 59–72), 58% (CI: 52–64), and 34% (CI: 28–42), respectively.
The day 100 and 2 year transplant-related mortality (TRM) was
3.6% (CI: 2–12) and 10.2% (CI: 7–20), respectively. Conditioning
regimen was not significantly associated with OS, DFS, relapse, or
TRM. The cumulative incidence of acute GVHD grade II-IV and
III-IVwas 40% (CI: 37–50) and 16% (CI: 12–27), respectively. Four-
teen of 21 patients with grade II GVHD had upper GI involvement
only. There was a trend for higher probability of acute GVHD in pa-
tients conditioned with BuCy compared with TBI and FluMel (64%,
49% and 34%, respectively)(p 5 0.12). The probability of chronic
GVHD was 45% (limited: 14%, extensive: 31%). Thrombotic mi-
croangiopathy (TMA) was a major complication which developed
in 19% of patients, significantly associated with BuCy (55%) com-
pared with TBI (25%) and FluMel (6.5%)(p5 0.005). TMA was re-
versible in all cases, managed by holding tacro and/or siro except for
two who required plasma exchange/hemodialysis. In summary, the
combination of tacro/siro is associated with a low TRM rate over 2
years. The encouraging results on acute GVHD in our study support
the ongoing phase III trial comparing tacro/siro versus tacro/MTX
(CTN 0402). However, TMA was frequently observed and the risk
was significantly greater with BuCy conditioning.245
PREDICTION OF VOD USING BIOMARKERS OF ENDOTHELIAL INJURY
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the occurrence of VOD in individuals remains challenging. Since the
primary mechanism of injury in VOD is conditioning-related dam-
age to hepatic sinusoidal endothelial cells and hepatocytes, we mea-
sured soluble biomarkers of endothelial injury in the peri-stem cell
transplant (SCT) period to determine if they correlated with the oc-
currence of VOD.
Methods: 59 patients who underwent HLA-matched donor SCT
received conditioning with cyclophosphamide (1800 mg/m2 x 2) and
TBI (14 Gy) and tacrolimus with sirolimus or methotrexate as
GVHD prophylaxis are included in this analysis. They are stratified
based on the occurrence of VOD (VOD1 n 5 18, VOD- n 5 41),
diagnosed by clinical, radiologic and pathologic criteria. Banked
samples collected after conditioning but prior to SCT (day -1) and
weekly after SCT (day 7, 14, 21) were thawed and analyzed using
commercial ELISA kits and quantified using a VersaMax plate
reader. Von Willebrand Factor (vWF) and thrombomodulin (TM)
were assayed in plasma; E-selectin and soluble intercellular adhesion
molecule-1 (ICAM) were assayed in serum. Assays were performed
in duplicate and the mean of two assays were analyzed. Not all pa-
tients had every time point analyzed due to missing specimens.
The within-sample results were compared using the 2-sided Wil-
coxon rank-sum test using the Bonferroni method to adjust for mul-
tiple comparisons.
Results: Among patients who received sirolimus, levels of vWF,
TM and ICAM were significantly different between VOD1 and
VOD- groups on day -1 (p # 0.04), day17 (p # 0.0001) and
day114 (p # 0.004). E-selectin was only predictive on day17 (p 5
0.009). Using pre-defined thresholds, vWF (.1400 IU/ml) and
TM (.100 ng/ml) levels on day 17 were 100% sensitive and
100% specific in predicting the occurrence of VOD. Biomarkers
could not reliably predict VOD among patients not treated with si-
rolimus. There were no differences in biomarkers among VOD- pa-
tients, suggesting that in the absence of VOD,markers of endothelial
injury are not elevated, even when sirolimus is used.
Conclusions: Plasma vWF and TM and serum ICAM elevations
before and early after SCT can be used to predict the occurrence of
VOD in patients receiving sirolimus. This analysis demonstrates the
contribution of sirolimus to endothelial injury and VOD after SCT,
and may help select patients in whom prophylactic or pre-emptive
strategies against endothelial damage and VOD may be useful.246
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Pre-transplant CMV serostatus has been shown to be an adverse
risk factor in allo-HCT recipients. The consequences of CMV reac-
tivation after transplantation have not been extensively described in
theUCB setting.We analyzed the impact of pre-transplant CMV se-
ropositivity and CMV reactivation on UCBT outcomes. Between
1994 and 2007, 332 patients with malignancies underwent UCBT
at the University of Minnesota and 54% were CMV seropositive.
AllUCBunits were considered seronegative.While there was a trend
to greater day 100 TRM (p5 0.07), CMV seropositivity was not as-
sociated with survival (p 5 0.55) or relapse (p 5 0.78). For the 180
CMV seropositive patients, the median age at UCBT was 51 years
(range 6–68). Myeloablative conditioning consisting of cyclophos-
phamide (CY) and TBI 13.2 Gy, with ATG (n5 31, 25%) or fludar-
abine (FLU, n5 91, 75%).Myeloablative conditioning was followed
by single (n 5 56, 46%) or double (n 5 66, 54%) UCBT. Reduced
intensity conditioning (RIC) consisted of CY, FLU and TBI 2 Gy
and was followed by double UCBT in all 58 patients. GVHD pro-
phylaxis consisted of cyclosporine/methylprednisone (17%) or cy-
closporine/mycophenolate mofetil (83%). All patients had weekly
screening for CMV reactivation (by pp65 antigenemia or PCR)
and received acyclovir prophylaxis until day 100. The incidence of
CMV reactivation was 51% (92/180) with no difference in recipients
of a myeloablative vs. RIC (p 5 0.33). Among recipients of myeloa-
blative conditioning, CMV reactivation was similar regardless of
GVHD prophylaxis regimen (p 5 0.8). In univariate analysis, the
only variables associated with CMV reactivation were older age
